CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
2.690
-0.510 (-15.94%)
At close: Sep 15, 2026, 4:00 PM EDT
2.750
+0.060 (2.23%)
After-hours: Sep 15, 2026, 7:48 PM EDT
CytomX Therapeutics Employees
CytomX Therapeutics had 69 employees as of December 31, 2025. The number of employees decreased by 52 or -42.98% compared to the previous year.
Employees
69
Change (1Y)
-52
Growth (1Y)
-42.98%
Revenue / Employee
$265,261
Profits / Employee
-$1,197,899
Market Cap
586.15M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 69 | -52 | -42.98% | 69 | 0 |
| Dec 31, 2024 | 121 | -1 | -0.82% | 119 | 2 |
| Dec 31, 2023 | 122 | 4 | 3.39% | 120 | 2 |
| Dec 31, 2022 | 118 | -60 | -33.71% | 116 | 2 |
| Dec 31, 2021 | 178 | 32 | 21.92% | 174 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| 4D Molecular Therapeutics | 196 |
| MapLight Therapeutics | 133 |
| Neurogene | 131 |
| DBV Technologies | 126 |
| Aura Biosciences | 113 |
| Annexon | 92 |
| Zevra Therapeutics | 61 |
CTMX News
- 1 day ago - CytomX Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 6 days ago - CytomX Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 7 days ago - CytomX Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 7 days ago - CytomX Therapeutics Slides: Wells Fargo 21st Annual Healthcare Conference - Filings
- 14 days ago - CytomX Therapeutics to Present at Upcoming September Investor Conferences - GlobeNewsWire
- 19 days ago - CytomX Therapeutics gets Fast Track Designation for Varseta-M - TheFly
- 19 days ago - CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) - GlobeNewsWire
- 4 weeks ago - CytomX Therapeutics price target lowered to $11 from $12 at JPMorgan - TheFly